Amylyx Pharmaceuticals

Historical price data

Amylyx Pharmaceuticals is a commercial-stage biotech focused on developing novel therapies for neurodegenerative and metabolic diseases with significant unmet medical needs. Its foundational achievement is the FDA and Health Canada approval of AMX0035 (RELYVRIO/ALBRIOZA) for ALS, secured via accelerated approval based on Phase 2 data. The company's strategy leverages a modality-agnostic R&D approach to match investigational drugs with diseases where they can have the greatest mechanistic impact, as seen in its expanding pipeline which now includes a first-in-class GLP-1 antagonist for hypoglycemia and an antisense oligonucleotide for ALS. Amylyx is transitioning from a single-product company to a diversified portfolio player while navigating the critical confirmatory trial for its lead asset.

A modality-agnostic R&D approach focused on matching therapeutic mechanisms to disease pathophysiology, initially built on a dual-mechanism neuroprotection platform targeting endoplasmic reticulum stress and mitochondrial dysfunction.